Clearmind Medicine (Clearmind Medicine) Debt-to-Equity : 0.02 (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine Debt-to-Equity?

Clearmind Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $0.06 Mil. Clearmind Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $0.03 Mil. Clearmind Medicine's Total Stockholders Equity for the quarter that ended in Jan. 2024 was $5.04 Mil. Clearmind Medicine's debt to equity for the quarter that ended in Jan. 2024 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Clearmind Medicine's Debt-to-Equity or its related term are showing as below:

CMND' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03 Med: 0.01 Max: 0.14
Current: 0.02

During the past 7 years, the highest Debt-to-Equity Ratio of Clearmind Medicine was 0.14. The lowest was -0.03. And the median was 0.01.

CMND's Debt-to-Equity is ranked better than
87.85% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs CMND: 0.02

Clearmind Medicine Debt-to-Equity Historical Data

The historical data trend for Clearmind Medicine's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Debt-to-Equity Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Debt-to-Equity

Get a 7-Day Free Trial

-0.03

Clearmind Medicine Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	-	-	-	0.02

Competitive Comparison of Clearmind Medicine's Debt-to-Equity

For the Biotechnology subindustry, Clearmind Medicine's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearmind Medicine's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's Debt-to-Equity falls into.

Clearmind Medicine Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Clearmind Medicine's Debt to Equity Ratio for the fiscal year that ended in Oct. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0.711
	=	0.00

Clearmind Medicine's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.064	+	0.031)	/	5.041
	=	0.02

Clearmind Medicine (NAS:CMND) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Clearmind Medicine Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearmind Medicine (Clearmind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CWY0:Germany CWY0:Germany CMND:Canada

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.